Agenda Items

A. The DUR Board will review the following pharmacotherapies and recommend clinical criteria and/or interventions to ensure appropriate utilization:

1. Inhaled Antibiotics for Cystic Fibrosis
   (tobramycin inhalation - Bethkis, Kitabis, Tobi solution, Tobi Podhaler; aztreonam - Cayston)

2. Agents for Pulmonary Fibrosis
   (nintedanib - Ofev, pirfenidone - Esbriet)

3. Topical Antifungals for Onycomycosis
   (ciclopirox - Penlac, efinaconazole - Jublia, tavaborole - Kerydin)

4. Cystine Depleting Agents
   (Cysteamine Bitartrate - Cystagon, Procysbi)

5. Hepatitis C Virus - Recently Approved Therapies
   (ombitasvir/paritaprevir/ritonavir with dasabuvir - Viekira)

   The Hepatitis C Virus agenda item will also include a Preferred Drug Program (PDP) review of new clinical and financial information for the Hepatitis C – Direct Acting Antiviral therapeutic class (PDP class listed below). The Board will review new clinical and financial information and recommend preferred or non-preferred status for products within the therapeutic class.

   **Hepatitis C - Direct Acting Antivirals**
   Copegus (ribavirin), Harvoni (ledipasvir/sofosbuvir), Moderiba (ribavirin), Olysio (simeprevir), Rebetol (ribavirin), Ribapak (ribavirin), Ribasphere (ribavirin), ribavirin, Sovaldi (sofosbuvir), Victrelis (boceprevir), Viekira (ombitasvir/paritaprevir/ritonavir with dasabuvir)
The current preferred or non-preferred status of products in the Hepatitis C – Direct Acting Antiviral therapeutic class may be viewed at: https://newyork fhsc.com/downloads/providers/NYRx_PDP_PDL.pdf

B. DUR Program Updates:

1. Retrospective Evaluation of Clinical Editing

2. Prescriber Education Program

**Agenda Timeline** (subject to change based on meeting proceedings)

<table>
<thead>
<tr>
<th>Time</th>
<th>Agenda Item</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00 - 9:15</td>
<td>Welcome and Introductions</td>
</tr>
<tr>
<td>9:15 - 10:15</td>
<td>Public Comment Period*</td>
</tr>
<tr>
<td>10:15 - 12:30</td>
<td>Agenda Items (from list above)</td>
</tr>
<tr>
<td>12:30 - 2:00</td>
<td>Lunch/Executive Session</td>
</tr>
<tr>
<td>2:00 - 3:45</td>
<td>Agenda Items (from list above)</td>
</tr>
<tr>
<td>3:45 - 4:00</td>
<td>Final Comments and Adjournment</td>
</tr>
</tbody>
</table>

* Interested parties must notify the Department of Health (the Department) at least one (1) week prior to the meeting of their request to address the DUR Board during the public comment period. Requests may be made by phone (518-486-3209) or e-mail (dur@health.ny.gov). Public comments are limited to the specific topics on the agenda, must be brief (2 minutes), and the total comment period will not exceed sixty (60) minutes.

All written statements must be received in an electronic format (dur@health.ny.gov) up to one (1) week in advance of the meeting. Written statements should summarize key points and may not exceed two (2) pages in length. If the submission of clinical information greater than two (2) pages in length is needed, the information must be received at least two (2) weeks prior to the meeting date or the Board may not have ample time to review the information. Please contact Department staff by e-mail (dur@health.ny.gov) prior to sending any information greater than two (2) pages.

Note: All information must be submitted to the Department. Information should not be submitted directly to DUR Board members. The Department will ensure that all information received (according to the guidelines above) is available for DUR Board member review prior to the meeting.